 Avalon GloboCare Corp NASDAQ:AVCO announced a new study incorporating artificial intelligence AI-enhanced protein design technology that could accelerate development of therapeutic monoclonal antibodies to treat cancer. Developed by Avalon, the QTY code technology is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins for use in clinical applications, including drug development. 